Investors focused on the Medical space have likely heard of Amgen (AMGN Quick QuoteAMGN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Amgen is one of 817 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AMGN is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for AMGN's full-year earnings has moved 1.63% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

According to our latest data, AMGN has moved about 8.04% on a year-to-date basis. In comparison, Medical companies have returned an average of 0.02%. This means that Amgen is outperforming the sector as a whole this year.

Looking more specifically, AMGN belongs to the Medical - Biomedical and Genetics industry, a group that includes 327 individual stocks and currently sits at #85 in the Zacks Industry Rank. This group has lost an average of 17.64% so far this year, so AMGN is performing better in this area.

Going forward, investors interested in Medical stocks should continue to pay close attention to AMGN as it looks to continue its solid performance.